The Expression Heparanase in Term and Preterm Placentas
NCT ID: NCT03798964
Last Updated: 2022-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2019-01-23
2020-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to investigate the association between heparanase expression in the human placenta and preterm birth (PTB) .
The investigators hypothesize that an abnormal placentation causes relative placental ischemia that induces higher rates of heparanase expression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Pro-angiogenic Immune Cells in Human Pregnancies
NCT01177020
Evaluation of the Role of Plasma Procalcitonin in Prediction of Intra-amniotic Infection in Preterm Premature Rupture of Membrane
NCT02104791
The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta
NCT01279369
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
NCT01584323
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and to Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of Membranes
NCT02069587
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elective term cesarean
Low-risk women undergoing elective term cesarean section
Placental analysis
Analysis of placenta to determine expression of heparanase
Term vaginal delivery
Low-risk women undergoing term vaginal delivery
Placental analysis
Analysis of placenta to determine expression of heparanase
Preterm vaginal delivery
Women undergoing preterm vaginal delivery
Placental analysis
Analysis of placenta to determine expression of heparanase
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placental analysis
Analysis of placenta to determine expression of heparanase
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Multiple pregnancy
* Significant maternal illness
* Significant fetal anomaly
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hillel Yaffe Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rinat Gabbay-Benziv, MD
Role: PRINCIPAL_INVESTIGATOR
Hillel Yaffe Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hille Yaffe Medical Center
Hadera, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HYMC-0119-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.